Teriparatide products — Medical Mutual
Glucocorticoid-induced osteoporosis treatment
Initial criteria
- Patient is initiating or continuing systemic glucocorticoids
- AND patient has tried oral bisphosphonate with inadequate response after 12 months, fracture while on therapy, or intolerance; OR cannot take oral bisphosphonate due to swallowing difficulty, inability to remain upright, or GI disorder; OR has tried zoledronic acid injection (Reclast); OR has severe renal impairment (CrCl <35 mL/min), CKD, or osteoporotic/fragility fracture
- AND use of Teriparatide/Tymlos does not exceed 2 years per lifetime
Reauthorization criteria
- Continuation is allowed if therapy has not exceeded a maximum lifetime duration of 2 years.
Approval duration
1 year (initial); 1 year (reauth); max 2 years total